316 related articles for article (PubMed ID: 15581262)
41. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
[TBL] [Abstract][Full Text] [Related]
42. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
Allen C; Pitcock J
Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
[No Abstract] [Full Text] [Related]
43. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
Saylor K; Williams DW; Schuh KJ; Wietecha L; Greenbaum M
Curr Med Res Opin; 2010 Sep; 26(9):2087-95. PubMed ID: 20642391
[TBL] [Abstract][Full Text] [Related]
44. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
Adler LA; Wilens T; Zhang S; Dittmann RW; D'Souza DN; Schuh L; Durell TM
Clin Ther; 2012 Feb; 34(2):363-73. PubMed ID: 22285724
[TBL] [Abstract][Full Text] [Related]
45. Non-stimulant medications in the treatment of ADHD.
Banaschewski T; Roessner V; Dittmann RW; Santosh PJ; Rothenberger A
Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I102-16. PubMed ID: 15322961
[TBL] [Abstract][Full Text] [Related]
46. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
47. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
Sasané R; Hodgkins P; Meijer W
Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
[TBL] [Abstract][Full Text] [Related]
49. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
Kratochvil CJ; Vaughan BS; Harrington MJ; Burke WJ
Expert Opin Pharmacother; 2003 Jul; 4(7):1165-74. PubMed ID: 12831341
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
Santosh PJ; Sattar S; Canagaratnam M
CNS Drugs; 2011 Sep; 25(9):737-63. PubMed ID: 21870887
[TBL] [Abstract][Full Text] [Related]
51. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
Prasad S; Arellano J; Steer C; Libretto SE
Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
[TBL] [Abstract][Full Text] [Related]
52. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
53. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
54. Atomoxetine.
Simpson D; Perry CM
Paediatr Drugs; 2003; 5(6):407-15; discussion 416-7. PubMed ID: 12765489
[TBL] [Abstract][Full Text] [Related]
55. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
[TBL] [Abstract][Full Text] [Related]
56. [My child is so restless].
Schlamp D
MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
[TBL] [Abstract][Full Text] [Related]
57. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
Schwartz S; Correll CU
J Am Acad Child Adolesc Psychiatry; 2014 Feb; 53(2):174-87. PubMed ID: 24472252
[TBL] [Abstract][Full Text] [Related]
59. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
[TBL] [Abstract][Full Text] [Related]
60. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
Chang K; Nayar D; Howe M; Rana M
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]